Gabapentin
Product Images NDC 69336-106

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 69336-106). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sterling Knight Pharmaceuticals,llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig1 (Figure1)

A line graph depicting mean pain score over 8 weeks, comparing placebo treatment to Gabapentin 3600 mg/day. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period, showing a decrease in pain score for Gabapentin compared to placebo.*

FDA Label Image

Fig2 (Figure2)

This line graph shows the mean pain score over a 7-week period during a study comparing placebo with Gabapentin at daily doses of 1800 mg and 2400 mg. The x-axis represents weeks from baseline through week 7, and the y-axis indicates mean pain score. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period, illustrating decreasing pain scores over time for both Gabapentin doses compared to placebo.*

FDA Label Image

Fig3 (Figure3)

A bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) at different dosages across two studies. Study 1 shows 12% response for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Fig4 (Figure4)

A scatter plot chart showing the percentage difference versus daily dose in milligrams for gabapentin across three studies (a, b, and c). The chart includes data points for daily doses ranging approximately from 600 mg to 1800 mg, with percentage differences ranging from about 5% to 18%. Each study is represented by different colored markers: black squares for study a, gray squares for study b, and white squares for study c.*

FDA Label Image

Formula (Formula)

An illustration showing the formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and a correction factor for female patients, commonly used in pharmacokinetic assessments.*

FDA Label Image

Label (Label)

Label for Gabapentin Capsules, USP 300 mg from Sterling Knight Pharmaceuticals, LLC. The label states the product contains 1000 tablets and includes storage instructions to keep between 20° to 25°C, with excursions allowed from 15° to 30°C. It emphasizes dispensing in tight, child-resistant containers and notes the product is Rx only. The label includes the NDC 69336-106-10 and a barcode.*

FDA Label Image

Structure (Struture)

Chemical structure diagram of Gabapentin showing its molecular components and their arrangement.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.